Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020

• Published in: Pediatric neurology Vol. 144; pp. 19 - 25
• Main Authors: Håkansson, Samuel, Wickström, Ronny, Zelano, Johan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023
• Subjects: Anticonvulsants - therapeutic use; Antiseizure medication; Child; Child, Preschool; Childhood epilepsy; Epilepsy - drug therapy; Epilepsy - epidemiology; Female; Humans; Infant; Lamotrigine - therapeutic use; Levetiracetam - therapeutic use; Male; Medicin och hälsovetenskap; Oxcarbazepine - therapeutic use; Pediatrics; Pediatrik; Pharmacotherapy; Prescription patterns; Sweden - epidemiology; Triazines - adverse effects; Valproic Acid; Sweden; Pharmacotherapy; Childhood epilepsy; Antiseizure medication; Prescription patterns
• ISSN: 0887-8994; 1873-5150; 1873-5150
• DOI: 10.1016/j.pediatrneurol.2023.03.016

Background: Knowledge on antiseizure medication (ASM) use and retention for children with epilepsy is limited, partly because of extensive off-label use of newer drugs with limited registration. We used prescription data to study prescription patterns on a population-wide scale and compared the proportion of patients remaining on monotherapy of ASMs with and without formal indication for different age groups. Methods: A total of 14,681 individuals aged <18 years were included, using cross-referenced Swedish registers from 2007 to 2020. Kaplan-Meier retention rates were calculated for all ASMs. The most common pathways of the first three medications per patient were analyzed. Results: In children older than one month and up to age one year, monotherapy retention rates were the highest for oxcarbazepine, valproic acid, and carbamazepine. Among children aged one to five years, oxcarbazepine and levetiracetam were among ASMs that do not have a monotherapy indication in Sweden but still had high retention rates. In the age group five to 12 years, lamotrigine and oxcarbazepine had the highest retention rate. In males aged 12 to 18 years, valproic acid was the most common choice followed by lamotrigine, whereas lamotrigine was the first choice of ASM for females, exceeding the second and third most common options levetiracetam and oxcarbazepine by a factor of two and three, respectively. Conclusion: Off-label medication is common in children with epilepsy but does not seem to be associated with lower retention. The restrictions regarding valproic acid for females of childbearing age seem to have been well implemented in Swedish neuropediatric care.